<div id="readability-page-1"><ul><li>Corbus Pharmaceuticals stock: An explosive 342% YTD surge</li></ul><p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Research analysts at B. Riley issued their FY2029 EPS estimates for Corbus Pharmaceuticals in a research note issued to investors on Wednesday, November 26th. B. Riley analyst M. Mamtani anticipates that the biopharmaceutical company will post earnings of ($4.82) per share for the year. B. Riley currently has a &#34;Strong-Buy&#34; rating and a $28.00 price target on the stock. The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.23) per share.</p><p>Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last issued its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.80) by ($0.10). </p><div><p><span></span><span>Get <strong>Corbus Pharmaceuticals</strong> alerts:</span></p></div><ul><li>Corbus Pharmaceuticals <span>NASDAQ: CRBP<span></span></span> Gives a Bold Buy Signal</li></ul><p>A number of other equities analysts also recently commented on CRBP. Royal Bank Of Canada dropped their price objective on Corbus Pharmaceuticals from $55.00 to $53.00 and set an &#34;outperform&#34; rating on the stock in a report on Thursday, November 13th. Oppenheimer dropped their price target on Corbus Pharmaceuticals from $56.00 to $53.00 and set an &#34;outperform&#34; rating on the stock in a research report on Wednesday, August 6th. HC Wainwright  reaffirmed a &#34;buy&#34; rating and set a $40.00 price objective on shares of Corbus Pharmaceuticals in a research report on Monday, October 20th. Wedbush raised their price objective on shares of Corbus Pharmaceuticals from $31.00 to $38.00 and gave the stock an &#34;outperform&#34; rating in a report on Monday, October 20th. Finally, Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Corbus Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst  has rated the stock with a Strong Buy rating, eight have issued  a Buy rating and two have issued  a Sell rating to the stock. According to MarketBeat.com, Corbus Pharmaceuticals currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $44.38.</p><p><b>View Our Latest Analysis on Corbus Pharmaceuticals</b></p><h2>Corbus Pharmaceuticals Trading Up 4.5%</h2><p>Shares of NASDAQ CRBP opened at $11.88 on Thursday. The business has a 50-day moving average price of $13.65 and a two-hundred day moving average price of $10.40. The firm has a market capitalization of $208.53 million, a PE ratio of -2.50 and a beta of 2.69. Corbus Pharmaceuticals has a one year low of $4.64 and a one year high of $20.56. </p><h2>Hedge Funds Weigh In On Corbus Pharmaceuticals</h2><p>Hedge funds and other institutional investors have recently modified their holdings of the business. ADAR1 Capital Management LLC bought a new stake in shares of  Corbus Pharmaceuticals in the 3rd quarter worth approximately $129,000.  Corton Capital Inc. bought a new position in  Corbus Pharmaceuticals in the 2nd quarter valued at $86,000.  Marshall Wace LLP purchased a new position in  Corbus Pharmaceuticals during the second quarter worth about $137,000.  Baker Avenue Asset Management LP bought a new position in shares of  Corbus Pharmaceuticals in the second quarter worth approximately $138,000.  Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of  Corbus Pharmaceuticals during the 2nd quarter valued at $141,000. Hedge funds and other institutional investors own  64.64% of the company's stock. </p><h2>Insiders Place Their Bets</h2><p>In related news, CEO Yuval Cohen sold 18,660 shares of the company's stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $17.01, for a total transaction of $317,406.60. Following the sale, the chief executive officer owned 138,187 shares in the company, valued at $2,350,560.87. This represents a 11.90% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CFO Sean F. Moran sold 12,981 shares of the company's stock in a transaction that occurred on Friday, October 24th. The stock was sold at an average price of $17.02, for a total value of $220,936.62. Following the transaction, the chief financial officer directly owned 73,313 shares in the company, valued at $1,247,787.26. The trade was a 15.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 41,674 shares of company stock valued at $713,870 in the last three months. 3.60% of the stock is owned by insiders. </p><h2>Corbus Pharmaceuticals Company Profile</h2> (Get Free Report)<p>Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Corbus Pharmaceuticals</li><li>How to Buy Cheap Stocks Step by Step</li><li>Tesla Just Got Called a “Must Own” Stock—Here’s Why</li><li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li><li>Why Gold Loves Trump as Much as Trump Loves Gold</li><li>Stock Average Calculator      </li><li>Google's Gemini 3 Sends Broadcom Soaring: TPUs Take Center Stage</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCUA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Corbus Pharmaceuticals Right Now?</h2><p>Before you consider Corbus Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corbus Pharmaceuticals wasn't on the list.</p><p>While Corbus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CRBP

<p>B. Riley forecasts Corbus Pharmaceuticals' FY2029 EPS at ($4.82) per share, maintaining a "Strong-Buy" rating with a $28.00 price target. Analysts have mixed ratings, with a consensus "Moderate Buy" and a $44.38 price target. The stock surged 342% YTD, trading at $11.88. Hedge funds own 64.64% of shares, and insiders recently sold shares. Corbus develops CRB-701, targeting Nectin-4 on cancer cells.</p>

What is B. Riley's Forecast for CRBP FY2029 Earnings?